No Data
BofA Securities Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $14
Bank of America Securities Sticks to Their Hold Rating for Vir Biotechnology (VIR)
Vir Biotechnology Down Over 14%, on Pace for Largest Percent Decrease Since July 2023 -- Data Talk
Vir Biotechnology Is Maintained at Outperform by Leerink Partners
Vir Biotechnology Analyst Ratings
Express News | Vir Biotechnology Inc : Leerink Partners Raises Target Price to $20 From $18